FR2938332B1 - Test predictif de la neutralisation de l'activite asparaginase - Google Patents

Test predictif de la neutralisation de l'activite asparaginase

Info

Publication number
FR2938332B1
FR2938332B1 FR0857604A FR0857604A FR2938332B1 FR 2938332 B1 FR2938332 B1 FR 2938332B1 FR 0857604 A FR0857604 A FR 0857604A FR 0857604 A FR0857604 A FR 0857604A FR 2938332 B1 FR2938332 B1 FR 2938332B1
Authority
FR
France
Prior art keywords
neutralization
asparaginase activity
predictive test
predictive
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0857604A
Other languages
English (en)
Other versions
FR2938332A1 (fr
Inventor
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0857604A priority Critical patent/FR2938332B1/fr
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to JP2011535120A priority patent/JP5771149B2/ja
Priority to ES09747859.8T priority patent/ES2447165T3/es
Priority to CA2743020A priority patent/CA2743020C/fr
Priority to KR1020117012739A priority patent/KR101803027B1/ko
Priority to US13/127,756 priority patent/US8852880B2/en
Priority to AU2009312702A priority patent/AU2009312702B2/en
Priority to PCT/EP2009/064793 priority patent/WO2010052315A1/fr
Priority to EP09747859.8A priority patent/EP2358894B1/fr
Priority to CN200980154044.7A priority patent/CN102272323B/zh
Publication of FR2938332A1 publication Critical patent/FR2938332A1/fr
Priority to IL212643A priority patent/IL212643A/en
Application granted granted Critical
Publication of FR2938332B1 publication Critical patent/FR2938332B1/fr
Priority to US14/489,556 priority patent/US9580739B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G01N2333/982—Asparaginase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
FR0857604A 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase Expired - Fee Related FR2938332B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0857604A FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase
EP09747859.8A EP2358894B1 (fr) 2008-11-07 2009-11-06 Essai pour la prédiction de la neutralisation de l'activité de l'asparaginase
CA2743020A CA2743020C (fr) 2008-11-07 2009-11-06 Essai pour la prediction de la neutralisation de l'activite de l'asparaginase
KR1020117012739A KR101803027B1 (ko) 2008-11-07 2009-11-06 아스파라기나아제 활성의 중화를 예측하기 위한 시험법
US13/127,756 US8852880B2 (en) 2008-11-07 2009-11-06 Test for predicting neutralization of asparaginase activity
AU2009312702A AU2009312702B2 (en) 2008-11-07 2009-11-06 Test for predicting neutralization of asparaginase activity
JP2011535120A JP5771149B2 (ja) 2008-11-07 2009-11-06 アスパラギナーゼ活性の中和を推定するための検査法
ES09747859.8T ES2447165T3 (es) 2008-11-07 2009-11-06 Prueba para predecir la neutralización de actividad de asparaginasa
CN200980154044.7A CN102272323B (zh) 2008-11-07 2009-11-06 用于预测对天冬酰胺酶活性的中和作用的测试
PCT/EP2009/064793 WO2010052315A1 (fr) 2008-11-07 2009-11-06 Essai pour la prédiction de la neutralisation de l'activité de l'asparaginase
IL212643A IL212643A (en) 2008-11-07 2011-05-03 Methods for predicting asparaginase activity in a patient and asparaginase for the treatment of aspartaginase-sensitive pathologies
US14/489,556 US9580739B2 (en) 2008-11-07 2014-09-18 Test for predicting neutralization of asparaginase activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0857604A FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase

Publications (2)

Publication Number Publication Date
FR2938332A1 FR2938332A1 (fr) 2010-05-14
FR2938332B1 true FR2938332B1 (fr) 2011-11-25

Family

ID=40491016

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0857604A Expired - Fee Related FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase

Country Status (11)

Country Link
US (2) US8852880B2 (fr)
EP (1) EP2358894B1 (fr)
JP (1) JP5771149B2 (fr)
KR (1) KR101803027B1 (fr)
CN (1) CN102272323B (fr)
AU (1) AU2009312702B2 (fr)
CA (1) CA2743020C (fr)
ES (1) ES2447165T3 (fr)
FR (1) FR2938332B1 (fr)
IL (1) IL212643A (fr)
WO (1) WO2010052315A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR20140145148A (ko) * 2012-03-21 2014-12-22 에리테끄 파르마 급성 골수성 백혈병 치료를 위한 약제
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
LT3402491T (lt) 2016-01-11 2022-02-25 Rubius Therapeutics, Inc. Kompozicijos ir būdai, susiję su daugiamodalinėmis terapinėmis ląstelių sistemomis, skirti vėžio indikacijoms
WO2018232176A1 (fr) 2017-06-16 2018-12-20 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR408667A (fr) 1909-11-05 1910-04-02 Richard Alexander Katz Hangar de fortune pour ballons dirigeables
FR2873925B1 (fr) * 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
US20080145876A1 (en) * 2006-11-21 2008-06-19 University Of Southern California Poly(ethylene glycol) anti-body detection assays and kits for performing thereof
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas

Also Published As

Publication number Publication date
EP2358894A1 (fr) 2011-08-24
CN102272323A (zh) 2011-12-07
US8852880B2 (en) 2014-10-07
KR101803027B1 (ko) 2017-11-29
AU2009312702A1 (en) 2010-05-14
AU2009312702B2 (en) 2012-06-28
CA2743020A1 (fr) 2010-05-14
US20150071894A1 (en) 2015-03-12
JP5771149B2 (ja) 2015-08-26
KR20110097806A (ko) 2011-08-31
IL212643A (en) 2015-04-30
CA2743020C (fr) 2018-12-18
CN102272323B (zh) 2017-03-22
WO2010052315A1 (fr) 2010-05-14
US20120121570A1 (en) 2012-05-17
IL212643A0 (en) 2011-07-31
US9580739B2 (en) 2017-02-28
JP2012507998A (ja) 2012-04-05
EP2358894B1 (fr) 2014-01-08
ES2447165T3 (es) 2014-03-11
FR2938332A1 (fr) 2010-05-14

Similar Documents

Publication Publication Date Title
FR2938332B1 (fr) Test predictif de la neutralisation de l'activite asparaginase
BRPI0907918A2 (pt) Ácidos sulfoperoxicarxílicos, sua preparação e métodos de utilizção como agentes alvejantes e antimicrobianos
BRPI0814425A2 (pt) Diferenciação de células-tronco embrionárias humanas
BRPI0919448A2 (pt) rastreamento de folículos pilosos
BRPI1007939A2 (pt) "identificação de aspectos de consulta"
BRPI0814026A2 (pt) Modificação química de ácidos gordos maleatados
BRPI1012129A2 (pt) enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
BRPI0814894A2 (pt) Diferenciação de células-tronco embrionárias de ser humano.
FI20085488A0 (fi) Älykäs hammasharjamonitorointilaite
BRPI0921026A2 (pt) avaliação do sistema circulatório de um indivíduo
BRPI0914450A2 (pt) "equipamento de estrumental círurgico"
BRPI0919707A2 (pt) utilização de ácido graxo dessaturases de hemiselmis spp
BRPI0915523A2 (pt) distribuição de formulações secas de octreotídeo
FR2976082B1 (fr) Methode de determination de l'activite de degradation de la matrice de fibrine d'un agent de detersion
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0913477A2 (pt) "método para desenvolvimento de marcador diagnóstico"
BRPI0914316A2 (pt) predição de resposta de terapia antiviral
GB201013679D0 (en) Analysis of proposed trades
BRPI0921947A2 (pt) formulações de proteína terapêutica
BRPI0917417A2 (pt) mnétodos de tratar deficiência cognitiva
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant
BRPI0912043A2 (pt) métodos de tratamento de doença associada à cinesina meiótica
BRPI0818902A2 (pt) Ciclopentanos substituídos tendo atividade de prostaglandina
BRPI0915927A2 (pt) uso de inibiodores de hdac para o tratamento da doença de hodgkin
FR2930723B1 (fr) Orthese de cheville

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20230705